Google Alert - hepatitis c

[Guest guest]

Google News Alert for: hepatitis c

Anadys reports positive data on hepatitis C drugBusinessWeekAnadys Pharmaceuticals Inc. said Thursday that a potential hepatitis C drug met key goals in a midstage clinical trial. The company said 72 percent of ...See all stories on this topic

Idenix Shares Up On Favorable Hepatitis C Drug Trial ResultsWall Street JournalIdenix Pharmaceuticals Inc. (IDIX) reported favorable interim results for a drug that treats the virus that causes hepatitis C. Shares in the ...See all stories on this topic

Pharmasset jumps on hepatitis C study resultsBusinessWeekPharmasset Inc. on Thursday reported promising early results from a clinical trial of a hepatitis C drug candidate. The company is testing a drug candidate ...See all stories on this topic

Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three ...MarketWatch (press release)"With VX-222, we believe we have a unique opportunity to broaden our commitment to improving patient care in hepatitis C and to strengthen our leadership ...See all stories on this topic

Jurors chosen in first hepatitis C case to reach trialLas Vegas SunBy Cara McCoy (contact) A jury has been seated in the first case linked to the outbreak of hepatitis C in Southern Nevada to go to trial. ...See all stories on this topic

Achillion Presents Data From Studies of ACH-1625 in Hepatitis C at the EASL ...MarketWatch (press release)The hepatitis C virus is the most common cause of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 170 ...See all stories on this topic

Biotech and Pharma Focus on Hepatitis CMinyanville.comBy LaMotta Apr 15, 2010 1:30 pm While hepatitis C is certainly a disease that you would want to avoid, biotech and Big Pharma have both caught the bug. ...See all stories on this topic

90% hepatitis C patients remain safe after treatmentThe News InternationalBy Hanif Khalid A study has found that 90 per cent of Hepatitis C (genotype-3) patients stay free of virus after completion of one-year treatment. ...See all

stories on this topic

US HOT STOCKS: Google, Lions Gate Active In Late TradingWall Street JournalThe drug company said that in the study, 72% of hepatitis C patients who received its twice-daily ANA598 400-milligram treatment saw undetectable levels of ...See all stories on this topic

InterMune/Roche celebrate success in mid-stage hep C trialPharma TimesShares in US biotech InterMune rocketed this week on the success of a mid-stage trial of its hepatitis C candidate danoprevir, which is being developed with ...See all stories on this topic